Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron

P. Scuderi, B. Wetchler, Y. F. Sung, M. Mingus, S. DuPen, L. Claybon, J. Leslie, P. Talke, J. Apfelbaum, S. Sharifi-Azad, M. F. Williams

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Background: Postoperative nausea and vomiting following outpatient surgery can significantly delay discharge. This study evaluates the safety and efficacy of ondansetron (a new 5-HT3 antagonist) in the treatment of postoperative nausea and vomiting in patients following outpatient surgery. Methods: Five hundred outpatient surgical patients (53 male and 447 female), receiving general endotracheal anesthesia, were studied at ten centers. Patients were stratified by gender and received, in a randomized, double- blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively. Episodes of vomiting, nausea scores, adverse events, vital signs, and laboratory values were evaluated before and during the 24 h after study drug administration. Results: Complete response to study medication (no vomiting and/or retching, and no rescue antiemetic over the initial 0-2-h period) was more frequent in the ondansetron groups (1 mg 57%, 4 mg 61%, and 8 mg 57%) than in the placebo group (30%, P < .001). For the 0- 24-h study a complete response occurred in only 15% of the placebo group compared to 41%, 47%, and 47% of the 1-, 4-, and 8-mg ondansetron groups, respectively (P < .001 for all comparisons with placebo). Median nausea scores (range 0-10) during the initial observation period (0-2 h) were significantly lower for all doses of ondansetron (1.3, 0.8, 1.8 for 1, 4, and 8 mg, respectively) as compared with placebo (2.3). No significant differences occurred in hemodynamic stability, incidence of adverse events, or changes in laboratory values in the ondansetron groups compared to the placebo group. Conclusions: Ondansetron, in doses less than 8 mg, is a safe, effective antiemetic for treating postoperative nausea and vomiting.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalAnesthesiology
Volume78
Issue number1
StatePublished - 1993
Externally publishedYes

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Ondansetron
Postoperative Nausea and Vomiting
Ambulatory Surgical Procedures
Placebos
Nausea
Vomiting
Antiemetics
Therapeutics
Endotracheal Anesthesia
Vital Signs
General Anesthesia
Outpatients
Hemodynamics
Observation
Safety
Incidence
Pharmaceutical Preparations

Keywords

  • Antagonists, serotonin: ondansetron
  • Complications, postoperative: nausea; vomiting
  • Receptors, 5-HT: serotonin

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Scuderi, P., Wetchler, B., Sung, Y. F., Mingus, M., DuPen, S., Claybon, L., ... Williams, M. F. (1993). Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology, 78(1), 15-20.

Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. / Scuderi, P.; Wetchler, B.; Sung, Y. F.; Mingus, M.; DuPen, S.; Claybon, L.; Leslie, J.; Talke, P.; Apfelbaum, J.; Sharifi-Azad, S.; Williams, M. F.

In: Anesthesiology, Vol. 78, No. 1, 1993, p. 15-20.

Research output: Contribution to journalArticle

Scuderi, P, Wetchler, B, Sung, YF, Mingus, M, DuPen, S, Claybon, L, Leslie, J, Talke, P, Apfelbaum, J, Sharifi-Azad, S & Williams, MF 1993, 'Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron', Anesthesiology, vol. 78, no. 1, pp. 15-20.
Scuderi P, Wetchler B, Sung YF, Mingus M, DuPen S, Claybon L et al. Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology. 1993;78(1):15-20.
Scuderi, P. ; Wetchler, B. ; Sung, Y. F. ; Mingus, M. ; DuPen, S. ; Claybon, L. ; Leslie, J. ; Talke, P. ; Apfelbaum, J. ; Sharifi-Azad, S. ; Williams, M. F. / Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. In: Anesthesiology. 1993 ; Vol. 78, No. 1. pp. 15-20.
@article{7362265985354d9b89e371fc3f6c3686,
title = "Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron",
abstract = "Background: Postoperative nausea and vomiting following outpatient surgery can significantly delay discharge. This study evaluates the safety and efficacy of ondansetron (a new 5-HT3 antagonist) in the treatment of postoperative nausea and vomiting in patients following outpatient surgery. Methods: Five hundred outpatient surgical patients (53 male and 447 female), receiving general endotracheal anesthesia, were studied at ten centers. Patients were stratified by gender and received, in a randomized, double- blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively. Episodes of vomiting, nausea scores, adverse events, vital signs, and laboratory values were evaluated before and during the 24 h after study drug administration. Results: Complete response to study medication (no vomiting and/or retching, and no rescue antiemetic over the initial 0-2-h period) was more frequent in the ondansetron groups (1 mg 57{\%}, 4 mg 61{\%}, and 8 mg 57{\%}) than in the placebo group (30{\%}, P < .001). For the 0- 24-h study a complete response occurred in only 15{\%} of the placebo group compared to 41{\%}, 47{\%}, and 47{\%} of the 1-, 4-, and 8-mg ondansetron groups, respectively (P < .001 for all comparisons with placebo). Median nausea scores (range 0-10) during the initial observation period (0-2 h) were significantly lower for all doses of ondansetron (1.3, 0.8, 1.8 for 1, 4, and 8 mg, respectively) as compared with placebo (2.3). No significant differences occurred in hemodynamic stability, incidence of adverse events, or changes in laboratory values in the ondansetron groups compared to the placebo group. Conclusions: Ondansetron, in doses less than 8 mg, is a safe, effective antiemetic for treating postoperative nausea and vomiting.",
keywords = "Antagonists, serotonin: ondansetron, Complications, postoperative: nausea; vomiting, Receptors, 5-HT: serotonin",
author = "P. Scuderi and B. Wetchler and Sung, {Y. F.} and M. Mingus and S. DuPen and L. Claybon and J. Leslie and P. Talke and J. Apfelbaum and S. Sharifi-Azad and Williams, {M. F.}",
year = "1993",
language = "English (US)",
volume = "78",
pages = "15--20",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron

AU - Scuderi, P.

AU - Wetchler, B.

AU - Sung, Y. F.

AU - Mingus, M.

AU - DuPen, S.

AU - Claybon, L.

AU - Leslie, J.

AU - Talke, P.

AU - Apfelbaum, J.

AU - Sharifi-Azad, S.

AU - Williams, M. F.

PY - 1993

Y1 - 1993

N2 - Background: Postoperative nausea and vomiting following outpatient surgery can significantly delay discharge. This study evaluates the safety and efficacy of ondansetron (a new 5-HT3 antagonist) in the treatment of postoperative nausea and vomiting in patients following outpatient surgery. Methods: Five hundred outpatient surgical patients (53 male and 447 female), receiving general endotracheal anesthesia, were studied at ten centers. Patients were stratified by gender and received, in a randomized, double- blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively. Episodes of vomiting, nausea scores, adverse events, vital signs, and laboratory values were evaluated before and during the 24 h after study drug administration. Results: Complete response to study medication (no vomiting and/or retching, and no rescue antiemetic over the initial 0-2-h period) was more frequent in the ondansetron groups (1 mg 57%, 4 mg 61%, and 8 mg 57%) than in the placebo group (30%, P < .001). For the 0- 24-h study a complete response occurred in only 15% of the placebo group compared to 41%, 47%, and 47% of the 1-, 4-, and 8-mg ondansetron groups, respectively (P < .001 for all comparisons with placebo). Median nausea scores (range 0-10) during the initial observation period (0-2 h) were significantly lower for all doses of ondansetron (1.3, 0.8, 1.8 for 1, 4, and 8 mg, respectively) as compared with placebo (2.3). No significant differences occurred in hemodynamic stability, incidence of adverse events, or changes in laboratory values in the ondansetron groups compared to the placebo group. Conclusions: Ondansetron, in doses less than 8 mg, is a safe, effective antiemetic for treating postoperative nausea and vomiting.

AB - Background: Postoperative nausea and vomiting following outpatient surgery can significantly delay discharge. This study evaluates the safety and efficacy of ondansetron (a new 5-HT3 antagonist) in the treatment of postoperative nausea and vomiting in patients following outpatient surgery. Methods: Five hundred outpatient surgical patients (53 male and 447 female), receiving general endotracheal anesthesia, were studied at ten centers. Patients were stratified by gender and received, in a randomized, double- blind manner, 1, 4, or 8 mg ondansetron or placebo in response to nausea and/or vomiting postoperatively. Episodes of vomiting, nausea scores, adverse events, vital signs, and laboratory values were evaluated before and during the 24 h after study drug administration. Results: Complete response to study medication (no vomiting and/or retching, and no rescue antiemetic over the initial 0-2-h period) was more frequent in the ondansetron groups (1 mg 57%, 4 mg 61%, and 8 mg 57%) than in the placebo group (30%, P < .001). For the 0- 24-h study a complete response occurred in only 15% of the placebo group compared to 41%, 47%, and 47% of the 1-, 4-, and 8-mg ondansetron groups, respectively (P < .001 for all comparisons with placebo). Median nausea scores (range 0-10) during the initial observation period (0-2 h) were significantly lower for all doses of ondansetron (1.3, 0.8, 1.8 for 1, 4, and 8 mg, respectively) as compared with placebo (2.3). No significant differences occurred in hemodynamic stability, incidence of adverse events, or changes in laboratory values in the ondansetron groups compared to the placebo group. Conclusions: Ondansetron, in doses less than 8 mg, is a safe, effective antiemetic for treating postoperative nausea and vomiting.

KW - Antagonists, serotonin: ondansetron

KW - Complications, postoperative: nausea; vomiting

KW - Receptors, 5-HT: serotonin

UR - http://www.scopus.com/inward/record.url?scp=0027446215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027446215&partnerID=8YFLogxK

M3 - Article

C2 - 8424548

AN - SCOPUS:0027446215

VL - 78

SP - 15

EP - 20

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 1

ER -